Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 Study of Nivolumab in Relapsed or Refractory Follicular Lymphoma
2013-003645-42Phase 2Unknown
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in follicular lymphoma (FL), sponsored by Bristol Myers Squibb. Primary endpoint: Objective response rate (ORR). Status: unknown.
02
Drugs
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2013-003645-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003645-42.